Phathom Pharmaceuticals

OverviewSuggest Edit

Phathom Pharmaceuticals is a biopharmaceutical company focused on treating gastrointestinal diseases and disorders. The company offers Vonoprazan, a small molecule potassium-competitive acid blocker to treat gastroesophageal reflux disease, including erosive esophagitis, gastric and duodenal ulcer, and low dose aspirin-associated ulcer.
TypePublic
Founded2018
HQBuffalo Grove, IL, US
Websitephathompharma.com

Latest Updates

Employees (est.) (Sept 2019)16(+34%)
Share Price (Jul 2021)$32.7(-2%)
Cybersecurity ratingAMore

Key People/Management at Phathom Pharmaceuticals

Tadataka Yamada

Tadataka Yamada

Chairman
Terrie Curran

Terrie Curran

President, Chief Executive Officer & Director
Azmi Nabulsi

Azmi Nabulsi

Chief Operating Officer
Joe Hand

Joe Hand

Chief Administrative Officer
Michael Cola

Michael Cola

Director
Aditya Kohli

Aditya Kohli

Chief Business Officer
Show more

Phathom Pharmaceuticals Office Locations

Phathom Pharmaceuticals has offices in Buffalo Grove, Florham Park and Menlo Park
Buffalo Grove, IL, US (HQ)
2150 E Lake Cook Rd #800Buffalo
Florham Park, NJ, US
100 Campus Dr #102
Menlo Park, CA, US
70 Willow Rd
Show all (3)

Phathom Pharmaceuticals Financials and Metrics

Phathom Pharmaceuticals Revenue

USD

Net income (FY, 2020)

(129.1m)

EBIT (FY, 2020)

(125.7m)

Market capitalization (22-Jul-2021)

1.0b

Closing stock price (22-Jul-2021)

32.7

Cash (31-Dec-2020)

287.5m

EV

783.3m
Phathom Pharmaceuticals's current market capitalization is $1 b.
Annual
USDFY, 2018FY, 2019FY, 2020

General and administrative expense

1.2m6.9m27.5m

R&D expense

20.0k20.4m98.1m

Operating expense total

2.5m27.3m125.7m

EBIT

(1.2m)(106.2m)(125.7m)
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020

General and administrative expense

1.8m4.5m5.2m

R&D expense

4.5m15.9m14.9m

Operating expense total

6.3m20.4m20.0m

Depreciation and amortization

77.0k
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

879.0k243.8m287.5m

Prepaid Expenses

11.8m3.9m

Current Assets

902.0k255.6m291.4m

PP&E

463.0k986.0k
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

82.9m74.5m256.7m247.3m

Prepaid Expenses

3.2m5.2m1.4m

Current Assets

84.5m77.7m261.8m248.7m

PP&E

40.0k768.0k748.0k
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(1.3m)(255.1m)(129.1m)

Depreciation and Amortization

8.0k323.0k

Accounts Payable

2.3m24.0m

Cash From Operating Activities

(1.0m)(36.5m)(69.7m)
Quarterly
USDQ2, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(514.0k)(89.0m)(157.1m)(20.1m)(41.2m)

Depreciation and Amortization

2.0k52.0k129.0k

Accounts Payable

1.6m1.5m8.1m

Cash From Operating Activities

(452.0k)(6.0m)(13.1m)(11.4m)(20.8m)
Show all financial metrics

Phathom Pharmaceuticals Operating Metrics

Oct, 2019

Drugs in Development

1

Phase III Trials Products

1
Show all operating metrics

Phathom Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Phathom Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Phathom Pharmaceuticals Online and Social Media Presence

Embed Graph

Phathom Pharmaceuticals News and Updates

Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates

FLORHAM PARK, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 202…

Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints

FLORHAM PARK, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that in PHALCON-HP, its pivotal Phase 3 cli…

Phathom Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference

FLORHAM PARK, N.J., April 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will pa…

Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial

FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has completed patient enrollment in …

Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock

FLORHAM PARK, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offer…

Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)

Management and Key Opinion Leaders to discuss NERD and the vonoprazan NERD development program during virtual Investor Day webcast today at 1:00 PM (ET) Management and Key Opinion Leaders to discuss NERD and the vonoprazan NERD development program during virtual Investor Day webcast today at 1:00 PM…
Show more

Phathom Pharmaceuticals Frequently Asked Questions

  • When was Phathom Pharmaceuticals founded?

    Phathom Pharmaceuticals was founded in 2018.

  • Who are Phathom Pharmaceuticals key executives?

    Phathom Pharmaceuticals's key executives are Tadataka Yamada, Terrie Curran and Azmi Nabulsi.

  • How many employees does Phathom Pharmaceuticals have?

    Phathom Pharmaceuticals has 16 employees.

  • Who are Phathom Pharmaceuticals competitors?

    Competitors of Phathom Pharmaceuticals include Restech, Neopharmed Gentili and Abiogen Pharma.

  • Where is Phathom Pharmaceuticals headquarters?

    Phathom Pharmaceuticals headquarters is located at 2150 E Lake Cook Rd #800Buffalo, Buffalo Grove.

  • Where are Phathom Pharmaceuticals offices?

    Phathom Pharmaceuticals has offices in Buffalo Grove, Florham Park and Menlo Park.

  • How many offices does Phathom Pharmaceuticals have?

    Phathom Pharmaceuticals has 3 offices.